Drug Profile
Research programme: CNS disorder therapies - Marinus Pharmaceuticals
Alternative Names: Chelerythrine - MarinusLatest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Yale University
- Class Alkaloids; Phenanthridines
- Mechanism of Action Protein kinase C inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Bipolar disorders; Schizophrenia
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Bipolar-disorders in USA
- 16 Jul 2016 No recent reports of development identified for preclinical development in Schizophrenia in USA
- 13 Sep 2007 Preclinical trials in Bipolar disorders in USA (unspecified route)